Literature DB >> 16550475

Long circulating poly(ethylene glycol)-decorated lipid nanocapsules deliver docetaxel to solid tumors.

Mohamed Nabil Khalid1, Pierre Simard, Didier Hoarau, Alice Dragomir, Jean-Christophe Leroux.   

Abstract

PURPOSE: The purpose of this study was to evaluate the ability of poly(ethylene glycol)-coated lipid nanocapsules (LN) to deliver the highly potent hydrophobic anticancer drug docetaxel to solid tumors.
METHODS: Docetaxel-loaded nanocapsules (80-120 nm) were produced by a solvent-free phase inversion process and were coated with polyethylene glycol distearoylphosphatidylethanolamine conjugate by a postinsertion step. In vivo studies were conducted in mice bearing subcutaneously implanted C26 colon adenocarcinoma to assess the pharmacokinetics and biodistribution of both the drug and LN.
RESULTS: Incorporation of docetaxel into the LN dramatically increased the drug's biological half-life while providing substantial accumulation at the tumoral site. The pharmacokinetics and biodistribution pattern were found to depend on the specific surface area and shell composition of the nanocapsules.
CONCLUSION: This study demonstrates that docetaxel physically entrapped into a lipid colloidal drug carrier can be efficiently targeted to neoplastic tissues.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16550475     DOI: 10.1007/s11095-006-9662-5

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  33 in total

Review 1.  Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors.

Authors:  D C Drummond; O Meyer; K Hong; D B Kirpotin; D Papahadjopoulos
Journal:  Pharmacol Rev       Date:  1999-12       Impact factor: 25.468

2.  Polymer-drug compatibility: a guide to the development of delivery systems for the anticancer agent, ellipticine.

Authors:  Jubo Liu; Yuehua Xiao; Christine Allen
Journal:  J Pharm Sci       Date:  2004-01       Impact factor: 3.534

3.  Anti-tumor efficacy and biodistribution of intravenous polymeric micellar paclitaxel.

Authors:  X Zhang; H M Burt; G Mangold; D Dexter; D Von Hoff; L Mayer; W L Hunter
Journal:  Anticancer Drugs       Date:  1997-08       Impact factor: 2.248

4.  Insertion of poly(ethylene glycol) derivatized phospholipid into pre-formed liposomes results in prolonged in vivo circulation time.

Authors:  P S Uster; T M Allen; B E Daniel; C J Mendez; M S Newman; G Z Zhu
Journal:  FEBS Lett       Date:  1996-05-20       Impact factor: 4.124

5.  Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel.

Authors:  Nuhad K Ibrahim; Neil Desai; Sewa Legha; Patrick Soon-Shiong; Richard L Theriault; Edgardo Rivera; Bita Esmaeli; Sigrid E Ring; Agop Bedikian; Gabriel N Hortobagyi; Julie A Ellerhorst
Journal:  Clin Cancer Res       Date:  2002-05       Impact factor: 12.531

6.  Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue.

Authors:  M C Bissery; D Guénard; F Guéritte-Voegelein; F Lavelle
Journal:  Cancer Res       Date:  1991-09-15       Impact factor: 12.701

7.  Core-cross-linked polymeric micelles as paclitaxel carriers.

Authors:  Xintao Shuai; Thomas Merdan; Andreas K Schaper; Fu Xi; Thomas Kissel
Journal:  Bioconjug Chem       Date:  2004 May-Jun       Impact factor: 4.774

8.  Differential cytotoxic effects of docetaxel in a range of mammalian tumor cell lines and certain drug resistant sublines in vitro.

Authors:  B T Hill; R D Whelan; S A Shellard; S McClean; L K Hosking
Journal:  Invest New Drugs       Date:  1994       Impact factor: 3.850

9.  Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies.

Authors:  Tae-You Kim; Dong-Wan Kim; Jae-Yong Chung; Sang Goo Shin; Sung-Chul Kim; Dae Seog Heo; Noe Kyeong Kim; Yung-Jue Bang
Journal:  Clin Cancer Res       Date:  2004-06-01       Impact factor: 12.531

10.  NK105, a paclitaxel-incorporating micellar nanoparticle formulation, can extend in vivo antitumour activity and reduce the neurotoxicity of paclitaxel.

Authors:  T Hamaguchi; Y Matsumura; M Suzuki; K Shimizu; R Goda; I Nakamura; I Nakatomi; M Yokoyama; K Kataoka; T Kakizoe
Journal:  Br J Cancer       Date:  2005-04-11       Impact factor: 7.640

View more
  20 in total

1.  Predicting the solubility of the anti-cancer agent docetaxel in small molecule excipients using computational methods.

Authors:  Loan Huynh; Justin Grant; Jean-Christophe Leroux; Pascal Delmas; Christine Allen
Journal:  Pharm Res       Date:  2007-08-18       Impact factor: 4.200

2.  A novel polymer-lipid hybrid nanoparticle for efficient nonviral gene delivery.

Authors:  Jian Li; Ying-zi He; Wen Li; Yun-zhen Shen; Yu-ru Li; Yun-feng Wang
Journal:  Acta Pharmacol Sin       Date:  2010-03-29       Impact factor: 6.150

3.  Feasibility and effectiveness of inhaled carboplatin in NSCLC patients.

Authors:  Paul Zarogoulidis; Ellada Eleftheriadou; Iordanis Sapardanis; Vasiliki Zarogoulidou; Helliel Lithoxopoulou; Theodoros Kontakiotis; Nikolaos Karamanos; George Zachariadis; Maria Mabroudi; Athanasios Zisimopoulos; Kostantinos Zarogoulidis
Journal:  Invest New Drugs       Date:  2011-07-08       Impact factor: 3.850

Review 4.  PEGylation: a promising strategy to overcome challenges to cancer-targeted nanomedicines: a review of challenges to clinical transition and promising resolution.

Authors:  Zahid Hussain; Shahzeb Khan; Muhammad Imran; Muhammad Sohail; Syed Wadood Ali Shah; Marcel de Matas
Journal:  Drug Deliv Transl Res       Date:  2019-06       Impact factor: 4.617

Review 5.  Nanoemulsions in translational research-opportunities and challenges in targeted cancer therapy.

Authors:  Srinivas Ganta; Meghna Talekar; Amit Singh; Timothy P Coleman; Mansoor M Amiji
Journal:  AAPS PharmSciTech       Date:  2014-02-08       Impact factor: 3.246

6.  Multifunctional PEGylated 2C5-immunoliposomes containing pH-sensitive bonds and TAT peptide for enhanced tumor cell internalization and cytotoxicity.

Authors:  Erez Koren; Anjali Apte; Ankur Jani; Vladimir P Torchilin
Journal:  J Control Release       Date:  2011-12-13       Impact factor: 9.776

7.  Toxicological study and efficacy of blank and paclitaxel-loaded lipid nanocapsules after i.v. administration in mice.

Authors:  José Hureaux; Frédéric Lagarce; Frédéric Gagnadoux; Marie-Christine Rousselet; Valérie Moal; Thierry Urban; Jean-Pierre Benoit
Journal:  Pharm Res       Date:  2010-03       Impact factor: 4.200

8.  Phospholipon 90H (P90H)-based PEGylated microscopic lipospheres delivery system for gentamicin: an antibiotic evaluation.

Authors:  Mumuni Audu Momoh; Charles Okechukwu Esimone
Journal:  Asian Pac J Trop Biomed       Date:  2012-11

9.  Doxorubicin in TAT peptide-modified multifunctional immunoliposomes demonstrates increased activity against both drug-sensitive and drug-resistant ovarian cancer models.

Authors:  Anjali Apte; Erez Koren; Alexander Koshkaryev; Vladimir P Torchilin
Journal:  Cancer Biol Ther       Date:  2013-10-21       Impact factor: 4.742

Review 10.  PEGylation as a strategy for improving nanoparticle-based drug and gene delivery.

Authors:  Jung Soo Suk; Qingguo Xu; Namho Kim; Justin Hanes; Laura M Ensign
Journal:  Adv Drug Deliv Rev       Date:  2015-10-09       Impact factor: 15.470

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.